A single-treatment strategy that generates antigen-specific immune tolerance to durably stop autoimmune disease without broad immunosuppression.
Our Approach
Nodal Therapeutics, Inc. is a start-up developing a single-treatment strategy that can durably stop autoimmune disease by generating antigen-specific immune tolerance (ASIT).
The technology is nucleated from Prof. Chris Jewell's lab at the University of Maryland, with best-in-class efficacy data in 10 pre-clinical models, including long-lasting remission and the ability to halt or reverse disease in a durable manner with a single treatment. We have generated data in models of multiple sclerosis, type 1 diabetes, transplantation, and more.
Illustrative mechanism — a degradable depot placed directly in a lymph node turns the node into a tolerance factory.
Seminal Papers & Transformative Science
Proof-of-concept has been demonstrated in 10 pre-clinical models, as described in high-impact publications.
Non-Dilutive Funding
Our platform has been de-risked by over $10M in non-dilutive funding, both federal and from leading patient-centric organizations.
Venture Funding
Nodal is venture-backed with a successful pre-seed round.
Meet the Team
Founder
KOL in immune engineering, tolerance, and autoimmunity. Triple-endowed Professor, University of Maryland. Former CSO, Cartesian Therapeutics.
Director and Senior Advisor
20 years of industry experience including ASIT. Former CEO of Topas Therapeutics and EirGenix Biopharma BU; lead roles in several US and EU approvals.
Chief Operating Officer
CMC and manufacturing expertise, with 20 years of industry experience in directly relevant particle technology at Acusphere, Tarveda, and Lyra Therapeutics.
Director, Translational Medicine
10 years of experience in I&I R&D. Original ASIT lead in the Jewell Lab and postdoctoral fellow at Harvard.
Senior Advisor and SAB Member
ASIT pioneer and multiple sclerosis expert. Member of multiple National Academies.
Clinical and Regulatory
NIH-trained medical oncologist with 25+ years of oncology and immunology experience. Founder, COO and CMO at Cartesian Therapeutics.
Co-Founder
KOL in lymph node structure and function, immunology, and Tregs. Vice Chair of Research, University of Maryland Medical Center.
Toxicology
Toxicology expert with 25 years of industry experience at Solvay, Medigene, and Grünenthal.
Contact Us
For partnering, investment, or scientific enquiries, get in touch.
